Recap on positive Financial analysis

For Nektar Therapeutics, with its modest market cap of $193.7M, these results could be transformative. The CAR-T therapy market is projected to grow significantly and NKTR-255's potential to enhance existing CAR-T treatments positions it well for partnerships or licensing deals. The data showing superior complete response rates compared to historical benchmarks could translate to significant market opportunity, especially given the high unmet need in relapsed/refractory LBCL patients. The safety profile appears favorable, which is important for regulatory pathway and market adoption. While the trial size was small at 15 patients, the randomized, double-blind design adds credibility to the findings.